3.69
0.06 (1.52%)
| Previous Close | 3.63 |
| Open | 3.69 |
| Volume | 43,479 |
| Avg. Volume (3M) | 232,800 |
| Market Cap | 170,029,584 |
| Price / Sales | 5.26 |
| Price / Book | 11.81 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 |
| Profit Margin | -15.10% |
| Operating Margin (TTM) | -12.92% |
| Diluted EPS (TTM) | -0.120 |
| Quarterly Revenue Growth (YOY) | 17.50% |
| Total Debt/Equity (MRQ) | 22.83% |
| Current Ratio (MRQ) | 2.44 |
| Levered Free Cash Flow (TTM) | 1.05 M |
| Return on Assets (TTM) | -13.09% |
| Return on Equity (TTM) | -29.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | KORU Medical Systems, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 7.65% |
| % Held by Institutions | 51.77% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Aug 2025 | Announcement | KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 30 Jul 2025 | Announcement | KORU Medical Systems to Participate in the Canaccord Genuity 45th Annual Growth Conference |
| 16 Jul 2025 | Announcement | KORU Medical Systems to Report Second Quarter 2025 Financial Results on August 6, 2025 |
| 07 Jul 2025 | Announcement | KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer |
| 11 Jun 2025 | Announcement | KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |